Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics
Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit
Sep 08 2022
•
By
Dave Wallace
Teva’s “doomsday scenario” falls apart under scrutiny, GSK claims • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin